In an open-label extension of two phase III trials in non-radiographic and radiographic axial spondyloarthritis, bimekizumab over 3 years showed no new safety signals (90.4% had ≥1 adverse event; Candida 5.3/100 PY); at week 164, 57.0% had ASDAS low disease activity.
RCTn = 574
Baraliakos et al. Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results From 2 Phase III Studies